Table 3.
COPDGene | TESRA | Adjusted meta-analysis p-value | |||
---|---|---|---|---|---|
Variable | Beta coefficient | p-value° | Beta coefficient | p-value° | |
Percent LAA ≤ −910 HU | |||||
RAGE | −1.4 | 2.6 × 10−5 | −0.52 | 9.2 × 10−7 | 1.2 × 10 −9 |
ICAM1 | −3.2 | 9.2 × 10−6 | −0.37 | 3.4 × 10−4 | 1.5 × 10−7 |
CCL20# | −0.87 | 1.3 × 10−4 | −0.29 | 2.2 × 10−3 | N/A |
Mean lung attenuation at 15 th percentile | |||||
RAGE | 10.78 | 1.3 × 10−5 | 7.08 | 3.0 × 10−8 | 2.5 × 10 −10 |
ICAM1 | 32.3 | 1.1 × 10−9 | 5.14 | 4.5 × 10−5 | 6.0 × 10−11 |
AXL | 18.8 | 1.8 × 10−4 | 2.53 | 0.038 | 3.8 × 10−3 |
CCL20# | 6.44 | 8.2 × 10−5 | 4.45 | 1.3 × 10−4 | N/A |
*Presented is the regression analysis for each biomarker with an adjusted meta-analysis p value. LAA = low attenuation area; RAGE = Receptor for advanced glycosylation end products; ICAM1 = Intercellular Adhesion Molecule 1; CCL20 = Macrophage Inflammatory Protein-3 alpha; AXL = AXL Receptor Tyrosine Kinase;
°p values for COPDGene and TESRA are two-sided p values.
#CCL20 was a binary variable in COPDGene, therefore it is the presence CCL20 that is negatively associated with emphysema in COPDGene cohort, while CCL20 was a continuous variable in TESRA also associated negatively associated with more severe emphysema. Meta-analysis was not possible given difference in variables (N/A).